Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2016', provides an overview of the Progressive Multifocal Leukoencephalopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy - The report reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Progressive Multifocal Leukoencephalopathy therapeutics and enlists all their major and minor projects - The report assesses Progressive Multifocal Leukoencephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Progressive Multifocal Leukoencephalopathy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Progressive Multifocal Leukoencephalopathy Overview 6 Therapeutics Development 7 Pipeline Products for Progressive Multifocal Leukoencephalopathy - Overview 7 Pipeline Products for Progressive Multifocal Leukoencephalopathy - Comparative Analysis 8 Progressive Multifocal Leukoencephalopathy - Therapeutics under Development by Companies 9 Progressive Multifocal Leukoencephalopathy - Therapeutics under Investigation by Universities/Institutes 10 Progressive Multifocal Leukoencephalopathy - Pipeline Products Glance 11 Early Stage Products 11 Progressive Multifocal Leukoencephalopathy - Products under Development by Companies 12 Progressive Multifocal Leukoencephalopathy - Products under Investigation by Universities/Institutes 13 Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development 14 Neurimmune Holding AG 14 Pomona Ricerca S.R.L 15 Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Combination Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 23 Drug Profiles 25 (JCV + progressive multifocal leukoencephalopathy) (virus like particle) vaccine - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 EBT-103 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 IkT-001 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 IKT-014 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 imatinib mesylate - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 NI-307 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 PNJC-1 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Progressive Multifocal Leukoencephalopathy - Recent Pipeline Updates 33 Progressive Multifocal Leukoencephalopathy - Dormant Projects 34 Progressive Multifocal Leukoencephalopathy - Product Development Milestones 35 Featured News & Press Releases 35 May 21, 2014: Inhibikase Therapeutics Receives Orphan Drug Designation for treatment of Progressive Multifocal Leukoencephalopathy 35 Apr 25, 2013: Inhibikase Therapeutics To Present Data On IkT-001Pro At 5th International Congress On Polyomaviruses And Human Diseases 36 Aug 16, 2011: Inhibikase Therapeutics Receives FDA Clearance For Phase II Trial Of IkT-001 To Treat JC Virus Infection In Multiple Sclerosis Patients 36 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2016 7 Number of Products under Development for Progressive Multifocal Leukoencephalopathy - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, H1 2016 14 Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca S.R.L, H1 2016 15 Assessment by Monotherapy Products, H1 2016 16 Assessment by Combination Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 21 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Progressive Multifocal Leukoencephalopathy Therapeutics - Recent Pipeline Updates, H1 2016 33 Progressive Multifocal Leukoencephalopathy - Dormant Projects, H1 2016 34
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.